ALERT!

This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Transcatheter Aortic Valve Replacement in Low-Risk Patients With Symptomatic Severe Aortic Stenosis

Monday, October 22, 2018

Submitted by

Ruben Osnabrugge

Source

Source Name: Journal of the American College of Cardiology

Source URL: http://www.onlinejacc.org/content/72/18/2095

Author(s)

Ron Waksman, Toby Rogers, Rebecca Torguson, Paul Gordon, Afshin Ehsan, Sean R. Wilson, John Goncalves, Robert Levitt, Chiwon Hahn, Puja Parikh, Thomas Bilfinger, David Butzel, Scott Buchanan, Nicholas Hanna, Robert Garrett, Federico Asch, Gaby Weissman, Itsik Ben-Dor, Christian Shults, Roshni Bastian, Paige E. Craig, Hector M. Garcia-Garcia, Paul Kolm, Quan Zou, Lowell F. Satler, Paul J. Corso

The authors of this paper matched 200 low-risk transcatheter aortic valve implantation (TAVI) patients with similar surgical aortic valve replacement (SAVR) patients from 11 institutions using inverse probabilitiy weighting. At 30 days, the mortality rate was 0.0% in the TAVI group and 1.7% in the SAVR group, whereas the stroke rate was 0.0 % in the TAVI group and 0.6% in the SAVR group. Permanent pacemaker rates were similar (around 5 %). These results show that low-risk TAVI is safe and effective in the short run. The results will have to be confirmed by randomized trials results which are expected in the spring of 2019.